Connect with us

Technology

iHuman Inc. Announces First Quarter 2024 Unaudited Financial Results

Published

on

BEIJING, June 28, 2024 /PRNewswire/ — iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2024.

First Quarter 2024 Highlights

Revenues were RMB235.0 million (US$32.5 million), compared with RMB265.2 million in the same period last year.Gross profit was RMB168.1 million (US$23.3 million), compared with RMB185.6 million in the same period last year.Operating income was RMB17.5 million (US$2.4 million), compared with RMB56.7 million in the same period last year.Net income was RMB22.3 million (US$3.1 million), compared with RMB53.6 million in the same period last year.Average total MAUs[1] reached a record-high of 26.38 million, a year-over-year increase of 25.1%.

 

[1] “Average total MAUs” refers to the monthly average of the sum of the MAUs of each of the Company’s apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

 

Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, “We started 2024 on a positive note, as our team precisely and efficiently executed our product roadmap to ensure our continued leadership in capturing user engagement. Central to our industry-leading product offerings are our high-quality content and advanced technological capabilities. In the first quarter, we continued to drive meaningful enhancements to our portfolio by leveraging these two strengths. Specifically, we intensified efforts to enhance our AI technologies and deepened their integration into our products to provide more dynamic and personalized experiences for our users. In June, we launched a brand-new product, iHuman Smart Coder, a full-year course developed and designed by iHuman’s stellar team that was led by graduates from Tsinghua University. This course is designed to foster a scientific mindset and digital literacy for children by blending curated content with innovative, exploratory, interactive, and immersive activities. With a scientifically-structured curriculum benchmarked against accredited proficiency exams, the course aims to transform kids from coding novices to proficient problem solvers prepared for a digitalized future. It also offers kids comprehensive support through a three-tiered system: a chatbot for immediate queries, a real-time code debugging feature powered by our proprietary large language model, and personalized guidance from seasoned instructors. We are confident that this course will equip the young minds with the skills and confidence to navigate an ever-evolving futuristic world.

We have also enriched our existing products with more AI-enabled experiences. Within iHuman Magic Thinking, we introduced “Challenge”, a new AI-powered feature that focuses on number literacy. Leveraging advanced AI algorithms, the new feature dynamically adapts the difficulty of questions to users’ level, ensuring that young learners remain appropriately challenged. This facilitates effective practice while preventing kids from becoming excessively frustrated, thus maintaining their engagement and enthusiasm.

Beyond our domestic efforts, expanding our presence in international markets continues to be our strategic priority. Adhering to our product-driven strategy, we continued to drive market penetration by strengthening our product pipeline to meet the unique needs of international users. We recently expanded the Aha World brand with Aha Makeover, a customizable, DIY-fashion design app that offers young children a dynamic platform to unlock their creativity through personalized virtual styling experiences. Kids can choose from a diverse array of avatars, personalize their hairstyles, decorate their avatar with different accessories, and experiment with an extensive wardrobe for various occasions. Our cutting-edge AR technology then seamlessly integrates virtual and physical elements, offering kids an interactive experience where their creations come to life.

Furthermore, we are making more selected domestic products which we believe have cross-border appeal and audiences available beyond the Chinese mainland market. For example, we have recently rolled out bekids Library, the adapted version of iHuman Readers, a comprehensive leveled English reading app that we collaborate on with Oxford University Press. Now available in Macau and Taiwan, it offers a curated collection of more than 1,000 graded readers from Oxford University Press and caters to different proficiency levels and interests. bekids Library also allows kids to record and listen their independent reading, personalizing the reading experience for every child.

Moving forward, our focus remains on enhancing our core competencies and creating high-quality and popular products to promote the holistic development of young children.”

Ms. Vivien Weiwei Wang, Director and Chief Financial Officer of iHuman, added, “Throughout the first quarter, our steadfast commitment to product excellence continued to propel our business forward. Supported by high levels of user satisfaction and loyalty, our average total MAUs reached a record-high of 26.38 million, representing a year-over-year increase of 25.1%. Additionally, we recorded profitability for the ninth consecutive quarter. With ongoing profitability and healthy cash reserves, we have stepped up investments in several key strategic priorities. These include advancing AI research and development to elevate product value and user experience, expanding our product range to cater to a broader age demographic and increase total addressable market, and intensifying international marketing efforts to bolster our brand recognition globally. While these increased investments may temporarily impact our short-term profitability, we believe they are crucial for reinforcing our industry leadership, sustaining our long-term growth, and creating long-term value for our shareholders.”

First Quarter 2024 Unaudited Financial Results

Revenues

Revenues were RMB235.0 million (US$32.5 million), a decrease of 11.4% from RMB265.2 million in the same period last year, primarily reflecting the ongoing normalization from the exceptional performance in the same period last year, which was caused by a heightened demand driven by more indoor activities during the pandemic. 

Average total MAUs for the quarter reached a record-high of 26.38 million, an increase of 25.1% year-over-year from 21.09 million in the same period last year.

Cost of Revenues

Cost of revenues was RMB66.9 million (US$9.3 million), a decrease of 16.0% from RMB79.6 million in the same period last year, primarily due to decreased channel costs.

Gross Profit and Gross Margin

Gross profit was RMB168.1 million (US$23.3 million), compared with RMB185.6 million in the same period last year. Gross margin was 71.5%, compared with 70.0% in the same period last year.

Operating Expenses

Total operating expenses were RMB150.6 million (US$20.9 million), an increase of 16.9% from RMB128.8 million in the same period last year.

Research and development expenses were RMB67.9 million (US$9.4 million), an increase of 10.1% year-over-year from RMB61.7 million in the same period last year, primarily due to increased payroll related expenses.  

Sales and marketing expenses were RMB55.0 million (US$7.6 million), an increase of 36.0% from RMB40.4 million in the same period last year, primarily due to increased strategic spending on promotional activities, brand enhancement, and overseas expansion.

General and administrative expenses were RMB27.7 million (US$3.8 million), compared with RMB26.7 million in the same period last year.

Operating Income

Operating income was RMB17.5 million (US$2.4 million), compared with RMB56.7 million in the same period last year.

Net Income

Net income was RMB22.3 million (US$3.1 million), compared with RMB53.6 million in the same period last year.

Basic and diluted net income per ADS were RMB0.42 (US$0.06) and RMB0.41 (US$0.06), respectively, compared with RMB1.01 and RMB0.98 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

Deferred Revenue and Customer Advances

Deferred revenue and customer advances were RMB313.8 million (US$43.5 million) as of March 31, 2024, compared with RMB318.6 million as of December 31, 2023.

Cash, Cash Equivalents and Time Deposits

Cash, cash equivalents and time deposits were RMB1,131.3 million (US$156.7 million) as of March 31, 2024, compared with RMB1,213.8 million as of December 31, 2023. The decrease was primarily due to the payment of annual bonuses to employees in the first quarter.

Exchange Rate Information

The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of March 29, 2024, which was RMB7.2203 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

Non-GAAP Financial Measures

iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman’s management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company’s current operating performance and prospects in the same manner as management does, if they so choose.

Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates”  and similar statements. Statements that are not historical facts, including statements about iHuman’s beliefs and expectations, are forward-looking statements. Among other things, the description of the management’s quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman’s growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman’s filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About iHuman Inc.

iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-upbringing experience easier for parents and transforming intellectual development into a fun journey for children. Benefiting from a deep legacy that combines over two decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman’s unique, fun and interactive product offerings stimulate children’s natural curiosity and exploration. The Company’s comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children’s abilities in speaking, critical thinking, independent reading and creativity, and foster their natural interest in traditional Chinese culture. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children’s behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

For more information about iHuman, please visit https://ir.ihuman.com/

For investor and media enquiries, please contact:

iHuman Inc.
Mr. Justin Zhang
Investor Relations Director
Phone: +86 10 5780-6606
E-mail: ir@ihuman.com 

Christensen
In China
Ms. Alice Li
Phone: +86-10-5900-1548
E-mail: alice.li@christensencomms.com  

In the US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com  

 

iHuman Inc.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

except for number of shares, ADSs, per share and per ADS data)

December 31,

March 31,

March 31,

2023

2024

2024

RMB

RMB

US$

ASSETS

Current assets

Cash and cash equivalents 

1,213,767

890,805

123,375

Time deposits

240,521

33,312

Accounts receivable, net

60,832

68,068

9,427

Inventories, net

16,518

17,247

2,389

Amounts due from related parties

1,810

2,850

395

Prepayments and other current assets

89,511

93,567

12,959

Total current assets

1,382,438

1,313,058

181,857

Non-current assets

Property and equipment, net

6,169

5,504

762

Intangible assets, net

23,245

22,080

3,058

Operating lease right-of-use assets

3,648

3,235

448

Long-term investment

26,333

26,333

3,647

Other non-current assets

8,662

8,286

1,146

Total non-current assets

68,057

65,438

9,061

Total assets

1,450,495

1,378,496

190,918

LIABILITIES

Current liabilities

Accounts payable

22,139

21,556

2,985

Deferred revenue and customer advances

318,587

313,790

43,459

Amounts due to related parties

4,428

22,710

3,145

Accrued expenses and other current liabilities

143,677

94,054

13,026

Dividend payable

37,525

5,197

Current operating lease liabilities

1,927

1,823

252

Total current liabilities

490,758

491,458

68,064

Non-current liabilities

Non-current operating lease liabilities

1,933

1,495

207

Total non-current liabilities

1,933

1,495

207

Total liabilities

492,691

492,953

68,271

SHAREHOLDERS’ EQUITY

Ordinary shares (par value of US$0.0001 per share,
    700,000,000 Class A shares authorized as of
    December 31, 2023 and March 31, 2024; 125,122,382
    Class A shares issued and
119,704,787 outstanding as
    of December 31, 2023; 125,122,382 Class A shares
    issued and 119,284,712 outstanding as of March 31,
    2024;  200,000,000 Class B shares authorized,
    144,000,000 Class B ordinary shares issued and
    outstanding as of December 31, 2023 and March 31,
    2024; 100,000,000 shares (undesignated) authorized,
    nil shares (undesignated) issued and outstanding as of
    December 31, 2023 and March 31, 2024)

185

185

26

Additional paid-in capital

1,088,628

994,532

137,741

Treasury stock

(16,665)

(17,922)

(2,482)

Statutory reserves

8,164

8,164

1,131

Accumulated other comprehensive income

17,955

18,745

2,596

Accumulated deficit

(140,463)

(118,161)

(16,365)

Total shareholders’ equity

957,804

885,543

122,647

Total liabilities and shareholders’ equity

1,450,495

1,378,496

190,918

 

iHuman Inc.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)
except for number of shares, ADSs, per share and per ADS data)

For the three months ended

March 31,

March 31,

March 31,

2023

2024

2024

RMB

RMB

US$

Revenues

265,203

235,003

32,548

Cost of revenues

(79,636)

(66,892)

(9,264)

Gross profit

185,567

168,111

23,284

Operating expenses

Research and development expenses

(61,673)

(67,923)

(9,407)

Sales and marketing expenses

(40,435)

(54,995)

(7,617)

General and administrative expenses

(26,735)

(27,724)

(3,840)

Total operating expenses

(128,843)

(150,642)

(20,864)

Operating income

56,724

17,469

2,420

Other income, net

6,082

9,010

1,248

Income before income taxes

62,806

26,479

3,668

Income tax expenses

(9,160)

(4,177)

(579)

Net income

53,646

22,302

3,089

Net income per ADS:

   – Basic

1.01

0.42

0.06

   – Diluted

0.98

0.41

0.06

Weighted average number of ADSs:

   – Basic

52,953,297

52,729,148

52,729,148

   – Diluted

54,763,570

54,691,599

54,691,599

Total share-based compensation expenses included in:

Cost of revenues

98

40

6

Research and development expenses

638

457

63

Sales and marketing expenses

379

46

6

General and administrative expenses

1,292

301

42

 

iHuman Inc.

UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

 (Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)
except for number of shares, ADSs, per share and per ADS data)

For the three months ended

March 31,

March 31,

March 31,

2023

2024

2024

RMB

RMB

US$

Operating income

56,724

17,469

2,420

Share-based compensation expenses

2,407

844

117

Adjusted operating income

59,131

18,313

2,537

Net income

53,646

22,302

3,089

Share-based compensation expenses

2,407

844

117

Adjusted net income

56,053

23,146

3,206

Diluted net income per ADS

0.98

0.41

0.06

Impact of non-GAAP adjustments

0.04

0.01

0.00

Adjusted diluted net income per ADS

1.02

0.42

0.06

Weighted average number of ADSs – diluted

54,763,570

54,691,599

54,691,599

Weighted average number of ADSs – adjusted

54,763,570

54,691,599

54,691,599

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ihuman-inc-announces-first-quarter-2024-unaudited-financial-results-302185388.html

SOURCE iHuman Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Macrogen Consortium win tender for National Bio Big Data Project

Published

on

By

Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium.

SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ — Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

The National Bio Big Data Project project has been running in Korea as a pilot project since 2020. During this period about 20,000 genomes were analysed, 10,000 of these including people with a rare disease. The ultimate goal is to enable precision medicine by building a reference genome for about 770,000 Koreans by 2028 and a total of 1 million by 2032.  

“Being a part of this step change to improving public health in Korea through the voluntary collection and analysis of genomic, clinical and life record information from the general public, is paramount to ensure precision medicine becomes a standard of care for all Koreans,” said Changhoon Kim, CEO Macrogen.

“Illumina is pleased to be a part of the Korean bio industry ecosystem and to participate in such an important national project. We look forward to contributing to Korea by bringing our expertise and lessons learned from our direct involvement in leading pop gen projects around the world,” said Robert McBride, General Manager of Illumina Korea.

People across the globe have very similar genes but a small number of variants between populations can impact health. For example, some variants are associated closely with particular diseases such as cystic fibrous.[1]These variants can present differently in populations and have a significant impact on how individuals respond to medicines and treatments. Therefore, it is beneficial for Koreans to have information available that is unique to them.

Worldwide, the number of pop gen projects is expanding rapidly, including the UK, Japan, Singapore, Qatar, the United Arab Emirates, and Nigeria.

“Population genome projects are growing worldwide with many programs reaching significant milestones. But despite this inequity remains with the majority of genome datasets being of European descent. This means we have a lot of information how to develop drugs for European populations but this doesn’t translate in any meaningful way to other nationalities, said Robert McBride.

Population genomics provides a platform for industry engagement and investment, specifically in the pharmaceutical, biotechnology, and data sectors. By integrating large, diverse data sets and using advanced computing technology (such as artificial intelligence or machine learning), health systems and partners are optimally positioned to unlock the power of the genome even further, while improving quality of life and care and fostering economic growth.

“Precision medicine is changing how diseases are treated and this benefits everyone. For patients, treatments often work better when decisions are based around an individual’s genome, for drug companies it can reduce cost of development and for governments there are long term savings related to less waste and healthier patients,” said Changhoon Kim.

References

[1] https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genomic-variation#:~:text=How%20do%20peoples’%20genomes%20vary,person%20responds%20to%20certain%20medications.

About Macrogen

Macrogen is a global genetic service provider, partnered with over 18,000 scientists in 150+ countries, and with more than 20 years of experience in the industry.

Established in 1997, from the Genome Medical Research Institute of Seoul National University, Macrogen has become a major service provider and consulting agent for government agencies, universities and research institutes around the world.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube

About the Consortium

Macrogen Consortium members include the following companies: DNA Link, Theragen Bio, and CG Invites

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/macrogen-consortium-win-tender-for-national-bio-big-data-project-302335981.html

SOURCE Illumina

Continue Reading

Technology

As 2025 IRS Mileage Rate Hits 70 Cents, Expert Warns: Ditch Risky Apps for Secure Paper Tracking

Published

on

By

Gig economy expert Ed Ryder warns against the risks of mileage tracking apps, and advocates using paper-based tracking methods instead. He introduces The Big Mileage Form, a secure alternative developed over two years to meet the specific needs of food delivery gig workers. Ryder highlights recent tech failures, like the July 2024 global IT outage, to underscore the vulnerabilities of digital solutions. The press release also mentions Ryder’s significant mileage deduction using his form and directs readers to GigCoach.net for additional resources, including a consumer tutorial to drive better food delivery outcomes and a gig coach training program.

PHILADELPHIA, Dec. 22, 2024 /PRNewswire-PRWeb/ — As the IRS announces a standard mileage rate of 70 cents per mile for 2025, gig economy expert Ed Ryder, who has completed over 10,000 deliveries with his own car using major food delivery platforms, urges fellow gig workers to reconsider their mileage tracking methods. While acknowledging the convenience of digital solutions, Ryder advocates for a return to secure, paper-based tracking to protect valuable mileage deductions.

With the mileage rate at 70 cents, accurate tracking is crucial for gig workers and small business owners. Mileage apps seem convenient, but they risk data loss from outages, glitches, and cyber attacks. Many overlook these significant dangers.

“With the mileage rate increasing to 70 cents, accurate tracking is more crucial than ever for gig workers and small business owners,” says Ryder, creator of The Big Mileage Form. “While mileage tracking apps seem convenient, they come with significant risks that many overlook. Network outages, app glitches, and cyber attacks can jeopardize months of data.”

Ryder points to the July 2024 global IT outage as a prime example of technology’s vulnerabilities. “A faulty software update caused mass airline disruptions and impacted other industries, catching major corporations off guard. This incident highlights that even in our digital age, software isn’t infallible. For me, I simply won’t trust mileage tracking apps with my most important tax deduction.”

To address these concerns, Ryder developed a comprehensive, paper-based solution. “I spent two years perfecting The Big Mileage Form, tailoring it to the specific needs of food delivery gig workers,” he explains. “At 11×17 inches, it provides ample space for detailed record-keeping and, crucially, it’s immune to software glitches, data breaches, and ransomware attacks.”

Ryder’s meticulous paper-based record-keeping resulted in a mileage deduction exceeding $19,000 on his 2023 federal taxes. “All my business-related miles are thoroughly documented on paper. I’m fully prepared to defend this deduction in case of an audit. This level of confidence is what I aim to provide other gig workers.”

“In today’s digital age, sometimes the most secure solution is the simplest one,” Ryder concludes. “My form not only ensures data security but also prepares users for potential IRS audits. It’s time to reconsider the old-fashioned, but reliable pen-and-paper method.”

For those interested in learning more about effective mileage tracking and other aspects of gig work, Ryder offers valuable resources on GigCoach.net. These include a tutorial for consumers titled ‘Fair Deal Delivery,’ which provides insights on how to improve food delivery outcomes. Additionally, experienced food delivery couriers can explore Ryder’s gig coach training program. Visit GigCoach.net to access these resources and learn more about The Big Mileage Form.

Media Contact

Ed Ryder, Match Experiment LLC, 1 484-493-8740, hello@ideamaned.com, gigcoach.net

View original content to download multimedia:https://www.prweb.com/releases/as-2025-irs-mileage-rate-hits-70-cents-expert-warns-ditch-risky-apps-for-secure-paper-tracking-302337779.html

SOURCE Gig economy expert Ed Ryder

Continue Reading

Technology

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Ascension Health Customers Whose Data May Have Been Compromised

Published

on

By

NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ — The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Ascension Health (“Ascension”). Ascension learned of suspicious activity on or about May 8, 2024. To join this case, go HERE.

About Ascension Health

Ascension is a prominent non-profit health system in the nation and operates under Catholic principles.

What happened?

On or about May 8, 2024, Ascension detected unauthorized activity in its computer systems. Ascension initiated an investigation, which included retaining consulting cybersecurity experts and notifying the FBI. The investigation determined that between May 7 and 8, 2024, a cybercriminal accessed files containing personal information about Ascension’s patients and employees. This information included names, medical records, payment details, insurance information, government identification numbers, and other personal data such as dates of birth and addresses. Approximately 6 million individuals have been affected by this data breach.

How can I protect my personal data?

If you receive a data breach notification, you must guard against possible misuse of your personal information, including identity theft and fraud, by regularly reviewing your account statements and monitoring your credit reports for suspicious or unauthorized activity. Additionally, you should consider legal options for mitigating such risks.

Edelson Lechtzin LLP is investigating a class action lawsuit to seek legal remedies for customers whose sensitive personal and patient data may have been compromised by the Ascension data breach.

For more information, please contact:

Marc H. Edelson, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492
Email: medelson@edelson-law.com
Web:  www.edelson-law.com 

About Edelson Lechtzin LLP
Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving data breaches, our lawyers focus on class and collective litigation in cases alleging securities and investment fraud, violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and catastrophic injuries.

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so counsel does not represent you unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing now. Your ability to share in any potential future recovery does not depend on serving as lead plaintiff.

View original content to download multimedia:https://www.prnewswire.com/news-releases/data-breach-alert-edelson-lechtzin-llp-is-investigating-claims-on-behalf-of-ascension-health-customers-whose-data-may-have-been-compromised-302337976.html

SOURCE Edelson Lechtzin LLP

Continue Reading

Trending